A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
PMV Pharmaceuticals, Inc
Mayo Clinic
Verastem, Inc.
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
Eli Lilly and Company
Novartis
Inhibrx Biosciences, Inc
VM Oncology, LLC
Incyte Corporation
Trishula Therapeutics, Inc.
Compugen Ltd
Intensity Therapeutics, Inc.
NextCure, Inc.
Teclison Ltd.
Inhibrx Biosciences, Inc
Second Affiliated Hospital of Guangzhou Medical University
National Cancer Institute (NCI)
Celldex Therapeutics
Mural Oncology, Inc
Corvus Pharmaceuticals, Inc.
Kineta Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Incyte Corporation
Syndax Pharmaceuticals
Gary Onik MD